CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Today Colossal, the de-extinction and species preservation company, announces numerous breakthrough successes in all stages ...

Colossal reports significant advancements in thylacine de-extinction efforts, including the generation of the highest quality ...

Successes across the de-extinction pipeline signal that the thylacine project is on track as Colossal continues its global ...

Colossal Biosciences, a US-based startup, has taken a major step towards resurrecting the lost species. The team has ...

Scientists claim to have made progress towards "de-extinction" and estimate their DNA sequence for the thylacine - or ...

BMO Capital analyst Kostas Biliouris maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price ...

The Minister of Justice and Attorney-General of the Federation, Prince Lateef Olasunkanmi Fagbemi (SAN), is scheduled to deliver the 39th ...

Cambridge company coding human cells for novel cures and a pioneer in synthetic biology, has successful defended its ...

Brain disorders are arguably the final frontier of medicine. Barriers that previously hindered the study of brain disorders can now be overcome through advances in induced pluripotent stem (iPS) cell ...